ClinicalTrials.gg
Not yet recruitingNCT07116239Updated Aug 11, 2025

Edoxaban Steady-State PK/PD in Adults With Nephrotic Syndrome

An interventional study of Edoxaban 60 mg and Enoxaparin 40 mg in Nephrotic Syndrome and Hypoalbuminemia, sponsored by Peking University People's Hospital. Not yet recruiting. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-08-11.

Sponsored by Peking University People's Hospital · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Primary completion was expected by Feb 2026, 9 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Non-randomized
Ages
18 Years to 70 Years
Sex
All
01

Study summary

A study to evaluate the impact of nephrotic syndrome on the steady state pharmacokinetics and pharmacodynamics of edoxaban compared to health volunteers, and whether edoxaban can provide an equivalent anticoagulant effect to enoxaparin sodium.

02

Conditions studied

  • Nephrotic Syndrome
  • Hypoalbuminemia

Keywords

  • edoxaban
  • nephrotic syndrome
  • hypoalbuminemia
  • enoxaparin
03

In context

Nephrotic Syndrome

192 studies on the registry are indexed under Nephrotic Syndrome; 65 are open to participants now.

This study's planned enrollment of 60 is above the median of 46 across 122 interventional studies indexed under Nephrotic Syndrome.

Browse Nephrotic Syndrome studies →

Lead sponsor

Peking University People's Hospital is the lead sponsor of 611 studies on the registry; 248 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Nephrotic syndrome Group:

    • Age between 18-70 years old
    • Diagnosed with nephrotic syndrome: proteinuria≥3.5 g/24h or morning urine protein/creatinine ratio ≥3.0g/g), with serum albumin \<30g/L present at the time of enrollment, with or without edema or hyperlipidemia
    • Calculated (CrCl) >50ml/min using the Cockcroft-Gault formula
    • Actual body weight >60kg, and within the range of 18.5-28kg/m2
    • Signed form
  2. Healthy volunteer Group:

    • Age between 18-70 years old
    • Serum albumin ≥40g/L
    • Calculated CrCl >50ml/min using the Cockcroft-Gault formula
    • Actual body weight >60kg, and body mass index within the range of 18.5-28kg/m2
    • Signed informed consent form

Exclusion criteria

Exclusion Criteria:

  • Serun albumin \<30 g/L for other reasons in patients with nephrotic syndrome as judged by the investigator
  • Prolonged PT, , APTT at baseline (defined as greater than the values)
  • count \<100×109/L or ≥300×109/L due to hematological diseases confirmed by laboratory tests
  • History of: gastrointestinal bleeding, intracranial hemorrhage, hemoptysis, or other clinically documented bleeding from internal organs within the last 3 months; surgery (except >3 days after renal without bleeding complications) or trauma. Bleeding complications after renal biopsy are defined as: ① bleeding (hematuria, perirenal hematoma, or arteriovenous fistula) that occur after renal biopsy requiring transfusion, resulting in altered hemodynamics, or requiring surgery or interventional treatment; ② symptomatic perirenal hematoma; and ③visible hematuria that persist for >3 days postoperatively.
  • A lesion or condition with a significant risk of major bleeding, such as current or recent gastrointestinal ulcer, malignant tumors with a high risk of bleeding, esophageal varices, arteriovenous malformations, vascular aneurysms, or major intravertebral or intracerebral vascular malformations.
  • Serious bleeding disorders as judged by the investigator
  • Systemic lupus erythematosus with or without renal damage
  • Bleeding or thrombophilia disorders as judged by the investigator
  • History of stroke
  • History of congestive heart failure (New York grade II or above) at the time of screening
  • Liver dysfunction (cirrhosis or >2×, and serum transaminases >3×, upper limit of normal)
  • Use of (but not limited to) the prescription medications that are inhibitors or inducers of and/or P-gp within the past 14 days:

    • CYP3A4 inducers (e.g., rifampicin, carbamazepine, phenytoin, etc.) ②CYP3A4 inhibitors (e.g., ketoconazole, ritonavir, clarithromycin, etc.)

      • P-gp inducers (e.g., apalutamide, rifampicin, etc.) ④ P-gp inhibitors (e.g., dronedarone, cyclosporine, erythromycin, ketoconazole, quinidine, verapamil, amiodarone, etc.) ⑤Selective serotonin reuptake inhibitors (SSRI) or serotonin-norepinephrine reuptake inhibitors (SNRI)
  • Use of antiplatelet and/ or anticoagulant agents within 5 half-lives (at least 7 days): including but not limited to heparin, heparin derivatives, aspirin, clopidogrel, prasugrel, nonsteroidal anti-inflammatory drugs, warfarin, rivaroxaban, dabigatran, apixaban, etc.
  • Pregnant or breastfeeding women or women of childbearing age without
  • Uncontrolled severe hypertension (SBP≥180mmHg, DBP≥110mmHg)
  • Conditions considered unsuitable for inclusion in this study, judged by investigator
  • Patients with to the active ingredient or other of the Edoxaban and enoxaparin sodium
  • History of immune-mediated heparin-induced thrombocytopenia (HIT) or presence of circulating antibodies within the previous 100 days.
  • Spinal or epidural anesthesia or local anesthesia within 24 hours prior to the administration of enoxaparin sodium and Edoxaban
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Edoxaban NS Group 1

    Patients with mild hypoalbuminemia (serum albumin \>25g/L and \<30g/L), taking edoxaban 60mg orally once daily

    Drug: Edoxaban 60 mg

  • Experimental
    Edoxaban NS Group 2

    Patients with severe hypoalbuminemia (serum albumin ≤25g/L), taking edoxaban 60mg orally once daily

    Drug: Edoxaban 60 mg

  • Active comparator
    LMWH NS Group 1

    Patients with mild hypoalbuminemia (serum albumin \>25g/L and \<30g/L), injecting enoxaparin sodium 0.4ml subcutaneously once daily

    Drug: Enoxaparin 40 mg

  • Active comparator
    LMWH NS Group 2

    Patients with severe hypoalbuminemia (serum albumin ≤25g/L), injecting enoxaparin sodium 0.4ml subcutaneously once daily

    Drug: Enoxaparin 40 mg

  • Other
    Healthy Volunteer Group

    Healthy volunteers, taking edoxaban 60mg orally once daily

    Drug: Edoxaban 60 mg

Interventions

  • DrugEdoxabanStudies of EdoxabanEdoxaban pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    film-coated tablet, manufactured by Daiichi Sankyo Europe GmbH

    Also known as: LIXIANAN

  • DrugEnoxaparinStudies of EnoxaparinEnoxaparin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    enoxaparin sodium, prefilled syringe of 0.4mL injectable solution, manufactured by SANOFI WINTHROP INDUSTRIE

    Also known as: CLEXANE

06

What researchers measure

Primary outcomes

  1. area under the steady-state plasma concentration-time curve (AUCss)

    ① Steady-state PK parameters of edoxaban in nephrotic syndrome patients versus healthy volunteers: area under the steady-state plasma concentration-time curve (AUCss)

    Time frame: Day 4 post-administation

  2. time to peak (Tmax)

    Steady-state PK parameters of edoxaban in nephrotic syndrome patients versus healthy volunteers: time to peak (Tmax)

    Time frame: Day 4 post-administation

  3. trough concentration at steady state (Css_min)

    Steady-state PK parameters of edoxaban in nephrotic syndrome patients versus healthy volunteers: trough concentration at steady state (Css\_min)

    Time frame: Day 4 post-administation

  4. peak concentration at steady state (Css_max)

    Steady-state PK parameters of edoxaban in nephrotic syndrome patients versus healthy volunteers: peak concentration at steady state (Css\_max)

    Time frame: Day 4 post-administation

  5. elimination half-life (t1/2)

    Steady-state PK parameters of edoxaban in nephrotic syndrome patients versus healthy volunteers: elimination half-life (t1/2)

    Time frame: Day 4 post-administation

  6. average steady-state plasma concentration (Css_av)

    Steady-state PK parameters of edoxaban in nephrotic syndrome patients versus healthy volunteers: average steady-state plasma concentration (Css\_av)

    Time frame: Day 4 post-administation]

  7. apparent volume of distribution (Vd/F)

    Steady-state PK parameters of edoxaban in nephrotic syndrome patients versus healthy volunteers: apparent volume of distribution (Vd/F)

    Time frame: Day 4 post-administation

  8. clearance (CL/F)

    Steady-state PK parameters of edoxaban in nephrotic syndrome patients versus healthy volunteers: clearance (CL/F)

    Time frame: Day 4 post-administation

  9. anti-FXa activity

    Steady-state PD parameters of edoxaban versus enoxaparin in nephrotic syndrome patients: anti-FXa activity

    Time frame: Day 4 post-administation

  10. prothrombin time (PT)

    Steady-state PD parameters of edoxaban versus enoxaparin in nephrotic syndrome patients: prothrombin time (PT)

    Time frame: Day 4 post-administation

  11. activated partial thromboplastin time(APTT)

    Steady-state PD parameters of edoxaban versus enoxaparin in nephrotic syndrome patients: activated partial thromboplastin time(APTT)

    Time frame: Day 4 post-administation

  12. antithrombin Ⅲ(AT-III)

    Steady-state PD parameters of edoxaban versus enoxaparin in nephrotic syndrome patients: antithrombin Ⅲ(AT-III)

    Time frame: Day 4 post-administation

  13. Protein C

    Steady-state PD parameters of edoxaban versus enoxaparin in nephrotic syndrome patients: Protein C

    Time frame: Day 4 post-administation

  14. Protein S

    Steady-state PD parameters of edoxaban versus enoxaparin in nephrotic syndrome patients: Protein S

    Time frame: Day 4 post-administation

  15. D-Dimer

    Steady-state PD parameters of edoxaban versus enoxaparin in nephrotic syndrome patients: D-Dimer

    Time frame: Day 4 post-administation

Other outcomes

  1. Safety Assessment

    Adverse events will be collected and coded according to the Medical Dictionary for Regulatory Activities (MedDRA)

    Time frame: from the date of informed consent form signature to day 8 post-administration

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Sep 2025; primary completion for Feb 2026, 5 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 25, 2025
First posted
Aug 11, 2025
StartEst.
Sep 2025
Primary completionEst.
Feb 2026
CompletionEst.
Feb 2026
Last update
Aug 11, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 11, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07116239
Responsible party
Sponsor
First posted
Aug 11, 2025
Start date
Sep 2025 (estimated)
Primary completion
Feb 2026 (estimated)
Completion
Feb 2026 (estimated)
Last update
Aug 11, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Edoxaban

Start the discussion